2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1026

Autoinflammatory Diseases, Particularly SAVI and Candle, Are Driven By Chronically Active Type I Interferons
Abstract Number: 1075

Automated Multiparameter Microscopy and Image Analysis: Next Generation Synovial Tissue Histology
Abstract Number: 1353

Autophagy Marker LC3 Accumulates in Immune-Mediated Necrotizing Myopathy Muscle Fibres
Abstract Number: 1057

Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts
Abstract Number: 1998

Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA
Abstract Number: 2418

Awareness of Fertility and Contraception Issues Among Women with Rheumatologic Diseases
Abstract Number: 1568

Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
Abstract Number: 2050

B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort
Abstract Number: 1561

B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Abstract Number: 180

Back to Bedside Teaching: Completion of a Rheumatology Rotation Significantly Increases Internal Medicine Residents’ Competency and Comfort with Comprehensive Knee Examinations
Abstract Number: 65

Bacteria-Derived Indole Drives Autoimmune Arthritis By Altering B Cell Glycosylation of Autoantibodies
Abstract Number: 2124

Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Abstract Number: 111

BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Abstract Number: 1908

Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects
Abstract Number: 1518

Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].